Abstract
Sulindac is a long-acting nonsteroidal anti-inflammatory drug (NSAID) widely used for the management of osteoarthritis, rheumatoid arthritis, ankylosing sponydlitis, and acute gouty arthritis. Reports of sulindac toxicity in the literature are rare. We report the case of a 22-year old male with a history of bipolar disorder who was brought to the emergency department after ingesting approximately 15 g of sulindac in a suicide attempt. He was found to have acute kidney injury and hyperbilirubinemia. Despite aggressive fluid resuscitation, his renal function progressively worsened requiring the initiation of hemodialysis. Ten days following ingestion of sulindac, he began to develop ischemic skin changes with a gangrenous appearance in his hands and feet. He continued to receive supportive treatment, and his acute kidney injury, hyperbillirubinemia, and ischemic skin necrosis eventually resolved. Clinicians should be aware of this long-acting NSAID and its ability to cause prolonged multisystem organ dysfunction.
Keywords: Clinoril, hepatotoxicity, nephrotoxicity, NSAID, overdose, sulindac.
Current Drug Safety
Title:Acute Kidney Injury, Hyperbilirubinemia, and Ischemic Skin Necrosis Due to Massive Sulindac Overdose
Volume: 10 Issue: 2
Author(s): John L. Vaughn, Kejal V. Shah, Maroun M. Ghossein, William L. Meyer and Robert B. Kirkpatrick
Affiliation:
Keywords: Clinoril, hepatotoxicity, nephrotoxicity, NSAID, overdose, sulindac.
Abstract: Sulindac is a long-acting nonsteroidal anti-inflammatory drug (NSAID) widely used for the management of osteoarthritis, rheumatoid arthritis, ankylosing sponydlitis, and acute gouty arthritis. Reports of sulindac toxicity in the literature are rare. We report the case of a 22-year old male with a history of bipolar disorder who was brought to the emergency department after ingesting approximately 15 g of sulindac in a suicide attempt. He was found to have acute kidney injury and hyperbilirubinemia. Despite aggressive fluid resuscitation, his renal function progressively worsened requiring the initiation of hemodialysis. Ten days following ingestion of sulindac, he began to develop ischemic skin changes with a gangrenous appearance in his hands and feet. He continued to receive supportive treatment, and his acute kidney injury, hyperbillirubinemia, and ischemic skin necrosis eventually resolved. Clinicians should be aware of this long-acting NSAID and its ability to cause prolonged multisystem organ dysfunction.
Export Options
About this article
Cite this article as:
Vaughn L. John, Shah V. Kejal, Ghossein M. Maroun, Meyer L. William and Kirkpatrick B. Robert, Acute Kidney Injury, Hyperbilirubinemia, and Ischemic Skin Necrosis Due to Massive Sulindac Overdose, Current Drug Safety 2015; 10 (2) . https://dx.doi.org/10.2174/157488631002150515150729
DOI https://dx.doi.org/10.2174/157488631002150515150729 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents in siRNA Delivery Employing Nanoparticles as Delivery Vectors
Recent Patents on DNA & Gene Sequences subject Index To Volume 2
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Cognitive Consequences of a Sustained Monocyte Type 1 IFN Response in HIV-1 Infection
Current HIV Research Editorial Review (Thematic Issue: An Update on Central Sensitivity Syndromes and the Issues of Nosology and Psychobiology)
Current Rheumatology Reviews Editorial (Thematic Issue: Antiinflammatory Treatment for Seemingly Non-inflammatory Disorders-Part 2)
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design Aceclofenac Organogels: In Vitro and In Vivo Characterization
Current Drug Delivery Lung Defence Mechanisms and Their Potential Role in the Prevention of Ventilator Associated Pneumonia
Current Respiratory Medicine Reviews Elicitation of Immune Responsiveness Against Antigenic Challenge in Age- Related Diseases: Effects of Red Wine Polyphenols
Current Pharmaceutical Design Editorial [Hot Topic: Latest Developments in the Treatment of Inflammatory Disease (Guest Editor: David Fairlie)]
Current Medicinal Chemistry TMJ Arthritis Imaging: Conventional Radiograph vs. CT Scan - Is CT Actually Needed?
Current Rheumatology Reviews Rofecoxib in Patients with Mild Cognitive Impairment: Further Analyses of Data from a Randomized, Double-Blind, Trial
Current Alzheimer Research The Promise of Slow Down Ageing May Come from Curcumin
Current Pharmaceutical Design Progress Towards the Development of Anti-Inflammatory Inhibitors of IKKβ
Current Topics in Medicinal Chemistry Recent Patents and New Strategies in the Treatment of Psoriasis
Recent Patents on Anti-Infective Drug Discovery Progress in Multiple Sclerosis Genetics
Current Genomics The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism
Current Pharmaceutical Design The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry Protease-Activated Receptor 2: Are Common Functions in Glial and Immune Cells Linked to Inflammation-Related CNS Disorders?
Current Drug Targets Information of ADME-Associated Proteins and Potential Application for Pharmacogenetic Prediction of Drug Responses
Current Pharmacogenomics